Core Insights - Bio-Path Holdings, Inc. has reported promising preclinical results for BP1001-A, indicating its potential as a treatment for obesity and related metabolic diseases in Type 2 diabetes patients [1][3] - BP1001-A works by downregulating Grb2 expression, which enhances insulin sensitivity and lowers blood glucose levels [2][3] Group 1: Preclinical Study Results - BP1001-A has been shown to reduce Grb2 protein expression in myoblast cells [2] - The treatment increased levels of phosphorylated AKT and phosphorylated FOXO-1 in myoblast and hepatoma cells in the presence of insulin [2] - These findings confirm that BP1001-A enhances insulin-induced metabolic events through the insulin/PI3K/AKT pathway [2] Group 2: Company Development Plans - Bio-Path has initiated animal studies to further confirm the efficacy of BP1001-A for obesity and related metabolic diseases in Type 2 diabetes patients [3] - If animal studies are successful, the company plans to start a first-in-human Phase 1 clinical trial in 2025 to validate safety, measure pharmacokinetics, and establish dosing for potential pivotal trials [3] Group 3: Company Overview - Bio-Path Holdings, Inc. is focused on developing DNAbilize®, a novel technology that has led to a pipeline of RNAi nanoparticle drugs [4] - The company's lead product candidate, prexigebersen (BP1001), is currently in a Phase 2 study for blood cancers, while BP1001-A is in a Phase 1/1b study for solid tumors [4] - Bio-Path is also evaluating BP1002 for blood cancers and solid tumors, and plans to file an IND application for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide [4]
Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity